Pfizer (PFE) R&D president has 816 shares withheld for taxes on RSU vesting

Rhea-AI Filing Summary

Pfizer Inc. President, R&D Christoffel Boshoff had 816 shares of common stock withheld on February 23, 2026 to cover tax obligations upon the vesting of restricted stock units, at a price of $27.06 per share. After this tax-withholding disposition, he directly holds 154,829 shares and indirectly holds 709 shares through a Rule 16b-3 plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOSHOFF CHRISTOFFEL

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		F		816(1)	D	$27.06	154,829	D
Common Stock								709	I	By Rule 16b-3 Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

	/s/ Shanice A. Reid, by power of atty, for Christoffel Boshoff	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pfizer (PFE) report for Christoffel Boshoff?

Pfizer reported a tax-related share withholding for Christoffel Boshoff. 816 common shares were withheld to satisfy tax obligations when restricted stock units vested, rather than an open-market sale, at a price of $27.06 per share on February 23, 2026.

How many Pfizer (PFE) shares were withheld for taxes in this Form 4?

The Form 4 shows 816 Pfizer common shares were withheld. These shares covered tax obligations arising from the vesting of restricted stock units, according to the filing footnote, and were valued at $27.06 per share on the transaction date of February 23, 2026.

Is the Pfizer (PFE) Form 4 for Christoffel Boshoff an open-market sale?

No, the Form 4 reflects a tax-withholding disposition, not an open-market sale. Shares were withheld to satisfy tax obligations when restricted stock units vested, which is categorized under transaction code F, rather than a voluntary market transaction.

How many Pfizer (PFE) shares does Christoffel Boshoff hold after this transaction?

After the transaction, Christoffel Boshoff directly holds 154,829 Pfizer common shares. He also indirectly holds 709 additional shares through a Rule 16b-3 plan, as disclosed in the filing’s ownership details for indirect holdings.

What does transaction code F mean in the Pfizer (PFE) Form 4 filing?

Transaction code F indicates a tax-withholding disposition in this context. It reflects payment of tax liability by delivering or withholding securities upon vesting of restricted stock units, rather than a standard buy or sell in the open market.

What role does Christoffel Boshoff hold at Pfizer (PFE) in this Form 4?

Christoffel Boshoff is identified as an officer of Pfizer, serving as President, R&D. This role is disclosed in the Form 4 reporting his tax-related share withholding tied to the vesting of restricted stock units.